EOLS Evolus
- 11.680
- +0.250+2.19%
Evolus News
Evolus to Report First Quarter Financial Results on May 7, 2024
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2024 financial results on Tuesday, May
Evolus Announces Publication Of Safety and Duration Data From Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau
The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appearance of moderate to severe glabellar lines presented at the 2023 ASDS A
AbbVie Working With FDA After Reports of Fake Botox Versions
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Evolus Insiders Sell US$3.0m Of Stock, Possibly Signalling Caution
Over the past year, many Evolus, Inc. (NASDAQ:EOLS) insiders sold a significant stake in the company which may have piqued investors' interest. When analyzing insider transactions, it is usually mor
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 9,651
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)
Needham: Reiterates Evolus (EOLS.US) rating and adjusted from buy to buy rating, target price is $22.00.
Needham: Reiterates Evolus (EOLS.US) rating and adjusted from buy to buy rating, target price is $22.00.
Needham Reiterates Buy on Evolus, Maintains $22 Price Target
Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.
Evolus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 65.54% Needham → $22 Reiterates Buy → Buy 03/08/2024 88.11% Stifel $23 → $25 Reiterates Buy → B
Evolus, Inc. (NASDAQ:EOLS) Is Favoured by Institutional Owners Who Hold 57% of the Company
Evolus Inc Announces Strategic Board Renewal Plans
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Evolus Insider Sold Shares Worth $1,344,604, According to a Recent SEC Filing
David Moatazedi, Director, President & CEO, on March 19, 2024, sold 96,566 shares in Evolus (EOLS) for $1,344,604. Following the Form 4 filing with the SEC, Moatazedi has control over a total of 695,8
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBiolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. As per the press release, Q4 earnings ca
Evolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth Investors
Survey Finds GLP-1 Users More Inclined to Get Aesthetic Procedures
Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS)
Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its Annual Results
Last week, you might have seen that Evolus, Inc. (NASDAQ:EOLS) released its full-year result to the market. The early response was not positive, with shares down 4.5% to US$14.07 in the past week.
Analysis
Price Target
No Data
